IntelGenx Corp. (IGX) Pitch Deck (2015): 17-Slide Breakdown

IntelGenx (IGX) positions itself as a leader in the innovative drug delivery space, specifically focusing on Oral Thin Films (OTF) and proprietary tablet technologies. The deck, dated November 24, 2015, highlights a total addressable market (TAM) of $19B, with $17B attributed to their VersaFilm platform. The company demonstrates significant commercial traction, citing record Q3 2015 revenue of $2.38M and European approval for RIZAPORT. A key differentiator presented is their in-house manufacturing capability, covering blending, coating, and packaging to ensure IP protection and higher margins…

Key takeaways

• The company targets a $19B total addressable market across its VersaFilm and VersaTab platforms (Slide 4).
• IntelGenx CEO Horst G. Zerbe is credited as the co-developer of Listerine breath strips, establishing immediate product-market fit credibility (Slide 2).
• The VersaFilm technology addresses specific medical needs for patients with difficulty swallowing, offering quicker action and improved compliance (Slide 6).
• Revenue showed significant growth, jumping from $0.45M in Q3 2014 to $2.38M in Q3 2015 (Slide 12).
• The product pipeline is diversified across multiple indications including Opioid Dependence ($1.78B market) and Schizophrenia ($5.2B market) (Slide 8).
• IntelGenx utilizes an in-house manufacturing approach to provide 'one-stop shopping' for pharmaceutical clients and protect IP (Slide 10).
• The team is highly technical, consisting of 18 employees, 8 of whom hold Ph.D. degrees (Slide 14).
• The deck lacks a specific 'Ask' slide detailing the amount of capital being raised or the intended use of funds.

Frequently asked questions

What is the primary technology IntelGenx is pitching?

The core technology is VersaFilm, an Oral Thin Film (OTF) delivery system. It is designed to improve patient compliance, especially for those who have difficulty swallowing tablets, and to provide faster onset of action by improving drug absorption. The deck also mentions VersaTab, a proprietary tablet technology, but VersaFilm represents the majority of the stated market opportunity ($17B of the $19B TAM).

How does the company generate revenue?

IntelGenx generates revenue through a combination of product sales and partnerships. Slide 8 shows they have already partnered with Par Pharmaceuticals for opioid dependence and Edgemont Pharmaceuticals for Major Depressive Disorder. Their Q3 2015 revenue reached $2.38M, a substantial increase from the previous year, indicating they are in the commercialization phase rather than just R&D.

What is the competitive advantage of their manufacturing process?

IntelGenx emphasizes an 'In-House Manufacturing Approach.' By controlling the blending, coating, and packaging processes, they reduce dependence on external partners. This 'one-stop shop' model is intended to increase profitability, protect intellectual property, and allow them to offer integrated pharmaceutical services to their clients.

Who are the key members of the leadership team?

The team is led by Dr. Horst G. Zerbe (Chairman, President & CEO), who co-founded Listerine breath strips and holds over 40 patents. Other key members include André Godin (CFO) with 25+ years in biotech, and Nadine Paiement (Director R&D), a co-inventor of the company's multilayer technology. The team is notably academic, with 8 Ph.D.s among 18 employees.

What major milestones has the company achieved?

Key milestones cited include achieving the first European marketing approval for RIZAPORT (a migraine treatment), reaching record Q3 revenue and profitability in 2015, and successfully completing pivotal bioequivalence studies for their VersaFilm platform. They also have two film products awaiting FDA approval as of the deck's date.

IntelGenx Corp. (IGX) pitch deck: the facts

Company

IntelGenx Corp. (IGX)

Year

2015

Stage

Public (TSX-V: IGX)

Slides

17

Sector

Pharmaceuticals / Drug Delivery

Deck type

Investor Presentation

Outcome

Active (Publicly Traded)

Headquarters

Saint-Laurent, Quebec, Canada

IntelGenx Corp. (IGX) pitch deck PDF

The full IntelGenx Corp. (IGX) deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the IntelGenx Corp. (IGX) pitch deck was used for

This is IntelGenx’s **January 2016 / late‑2015 investor presentation** for its TSX‑V listed entity (IGX), a 17‑slide deck aimed at public‑market investors rather than a private VC round. The deck positions IntelGenx as an oral thin film drug delivery company commercializing its proprietary VersaFilm™ platform, highlighting products for **migraines, erectile dysfunction, schizophrenia/bipolar I disorder** and several generic products via a strategic partnership with Chemo Group. The company uses the deck to explain the **advantages of oral thin film delivery**, its recent **European approval** of RIZAPORT® for migraines (Germany 2015), and its strategy of co‑development and licensing deals (RedHill Biopharma, Chemo Group, Grupo Juste, Pharmatronic) to enter global markets. Financial context in related 2015–2016 presentations emphasizes record 2015 revenue and profitability and facility build‑out, while SEC filings in 2017 show subsequent capital raising via debentures rather than a discrete private round tied solely to this deck.

Business model: IntelGenx is a specialty pharmaceutical company focused on developing and manufacturing **oral thin film drug delivery** products based on its proprietary **VersaFilm™** and VersaTab™ technologies, primarily through partnerships and licensing agreements with other pharma companies.

Year

2017

Industry

Pharmaceuticals / Drug Delivery / Oral Thin Film Technologies.

Round: Public company debenture financing (registered offering), following IntelGenx’s listing on TSX-V and OTCQX.

Raising: 2017 debenture offering registered on Form S-1, consisting of CA$1,000 principal amount per debenture, intended to fund capital expansion, clinical studies, product development, and working capital.

Raised: Minimum CA$7,000,000 aggregate principal amount targeted for debentures in the 2017 offering, as per the Form S-1; the exact amount ultimately raised is not specified in the retrieved materials.

Headquarters: Montreal area, Quebec, Canada (corporate address on Abrams Street in Ville Saint-Laurent, Quebec).

Use of funds as presented: Net proceeds to be used for capital expansion, clinical studies, product development, and general working capital requirements, according to the Form S-1.

What happened after the IntelGenx Corp. (IGX) deck

Following the 2015–2016 investor deck, IntelGenx successfully obtained and expanded European marketing approvals for its RIZAPORT® migraine oral film, entered into commercialization agreements in Spain and South Korea, deepened its generic product partnership with Chemo Group, built out a dedicated Montreal oral film manufacturing facility, and raised capital via a debenture offering to support fu

• European marketing approval for RIZAPORT® (rizatriptan oral thin film) for acute migraines in **Germany in October 2015*
• Binding and definitive **licensing agreements** for RIZAPORT® with **Grupo Juste** for Spain and certain territories and
• Execution of **strategic partnership with Chemo Group** for four generic products, granting Chemo an exclusive worldwide
• Construction and FDA pre‑approval inspection planning for a **17,000‑square‑foot oral film manufacturing plant in Montre
• Filing of a **Form S‑1 in April 2017** for a debenture offering with a minimum CA$7 million aggregate principal amount,

What the IntelGenx Corp. (IGX) deck got right

• Compelling articulation of oral thin film value proposition. The deck clearly articulates **advantages of oral thin film delivery**—reduced side effects, improved bioavailability, faster response time, and lifecycle management—connecting these to concrete strategies such as repurposing existing drugs and creating first‑to‑file generics where high technology barriers exist.
• Strong and diversified partner ecosystem. IntelGenx showcases **multiple named strategic partnerships** (RedHill Biopharma for migraines, Chemo Group for generics, Grupo Juste and Pharmatronic for territorial rights), demonstrating external validation and a partnership‑driven commercialization model rather than a pure R&D story.
• Lead asset with documented regulatory traction. The migraine lead product **RIZAPORT®** is backed by tangible progress—European marketing approval in Germany (2015) and Luxembourg (2017), plus licensing deals in Spain and South Korea—showing that IntelGenx has moved beyond concept to regulatory and commercial execution.
• Platform leveraged across multiple therapeutic areas. The deck presents a **robust, indication‑diverse pipeline** (migraines, erectile dysfunction, schizophrenia/bipolar, multiple generics) built on the same VersaFilm™ platform, which can be attractive for investors seeking platform leverage and multiple shots on goal.
• Aligned manufacturing infrastructure for oral films. IntelGenx highlights **manufacturing capabilities**, including a dedicated oral film facility in Montreal, aligning its technology story with tangible production capacity and the FDA’s planned pre‑approval inspection, which strengthens credibility around commercial readiness.
• Public‑company transparency and demonstrated revenue. Being a **publicly listed company (TSX-V: IGX, OTCQX: IGXT)** with record 2015 revenue and profitability provides transparency and signals a level of operational maturity beyond many early‑stage biotech ventures.

What could have been stronger

• Regulatory timelines presented optimistically without prior setback context. The deck makes multiple **forward projections and specific FDA submission/approval timelines** (e.g., USA NDA submissions and expected approvals in 2017–2018 for RIZAPORT® and Tadalafil VersaFilm™), but it does not clearly show historical reliability of IntelGenx’s regulatory timelines or discuss prior FDA setbacks (e.g., RIZAPORT® CRL in 2014), which later filings and press releases reveal.
• Limited financial detail on partnership economics. While the deck states that Chemo Group agreements have **“total value of 7 digits”** and that IntelGenx will receive upfront, milestone, R&D revenues, and profit sharing, it does not break down expected cash flows, margin impact, or specific financial terms, limiting an investor’s ability to quantify the economic significance of these partnerships.
• Pipeline breadth without deep evidence of differentiation or risk. The deck outlines an ambitious pipeline (migraines, ED, schizophrenia/bipolar, multiple generics) but provides little detail on **development stage, probability of success, or comparative competitive landscape** for each asset beyond headline timelines and basic descriptions.
• Sparse go‑to‑market and market access information. The presentation stresses the **advantages of oral thin film delivery** and mentions lifecycle management and repurposing, but offers limited concrete data on **market access, pricing strategy, or payer adoption**, which are critical for products like migraine therapies and ED treatments in competitive, genericizing markets.

How an investor would read this deck

What draws attention

• Scale and exclusivity of the **Chemo Group partnership** (scope of four generic products, exclusivity terms, and long‑term revenue potential).
• Regulatory and commercial trajectory of **RIZAPORT® for migraines**—European approvals (Germany 2015, Luxembourg 2017), FDA resubmission history, and status of U.S. commercialization partners.
• Clinical and regulatory path for **Tadalafil VersaFilm™** in the U.S. ED market, including timing vis‑à‑vis generic Cialis® competition and the Lilly patent license described in the deck.
• Development progress and safety profile of the **loxapine oral thin film** product for schizophrenia/bipolar I disorder, including pathway to approval and market positioning.
• Capacity, qualification, and utilization of the **Montreal oral film manufacturing plant**, and how capital expenditures and debenture financing translate into scalable revenue.

Risks that stand out

• Regulatory risk that **FDA or other regulators delay or reject** submissions (as occurred with RIZAPORT® in 2014), pushing out the timelines highlighted in the deck and affecting revenue projections.
• Execution risk in **commercial partnerships**—IntelGenx depends heavily on partners like RedHill, Chemo, Grupo Juste, and Pharmatronic for funding development, navigating regulatory processes, and commercializing products.
• Market risk that in crowded therapeutic areas (migraines, ED) IntelGenx’s oral films may not achieve significant payer or prescriber adoption versus entrenched tablets, generics, or other novel delivery forms.
• Financing and balance sheet risk, given capital‑intensive manufacturing build‑out and the need for ongoing funding (e.g., debentures) in a company that, while profitable in 2015, operates in a volatile small‑cap biotech environment.

Questions this deck invites

• What are the **current statuses** (approvals, launches, partnership economics) of the products highlighted in the deck: RIZAPORT® for migraines, Tadalafil VersaFilm™, and loxapine VersaFilm™?
• How did the **Chemo Group agreements** (four generic products) translate into actual submissions, approvals, and revenues, and what are the detailed financial terms (royalty rates, profit splits, milestones)?
• What were the **outcomes of the FDA interactions** for RIZAPORT® (original NDA, CRL, resubmission) and Tadalafil VersaFilm™, and how do they compare with the timelines promised in the deck?
• How has IntelGenx funded its manufacturing expansion and pipeline since this deck (e.g., 2017 debenture offering), and what is the resulting capital structure and dilution impact for shareholders?
• What competitive products (other oral films, ODT tablets, generics) exist in each target indication, and how does IntelGenx quantify its **clinical, convenience, and economic differentiation**?

What founders can take from the IntelGenx Corp. (IGX) deck

• A **platform‑technology deck** can be compelling when it anchors the story in concrete regulatory wins, like European approval of RIZAPORT® in Germany, and pairs technology claims with recognizable indications (migraines, ED, schizophrenia/bipolar).
• Demonstrating **named strategic partners** (RedHill, Chemo Group, Grupo Juste, Pharmatronic) with clear licensing structures and market territories strengthens credibility and clarifies the commercialization path for a drug‑delivery company.
• Explicitly linking platform advantages (oral thin film convenience, faster onset, lifecycle management) to **repurposing and generic strategies** shows how a technology can unlock both branded and generic opportunities.
• Including **forward‑looking regulatory and launch timelines** is useful for investors but should ideally be balanced with transparency about prior regulatory history (e.g., previous CRLs) to avoid perceived over‑optimism.
• For public‑company decks, pairing pipeline narratives with **recent financial performance** (record revenue and profitability) and manufacturing capacity build‑out helps investors assess near‑term sustainability alongside long‑term optionality.
• A focused emphasis on one or two **lead assets** (such as RIZAPORT®) with documented approvals and clearly defined next regulatory steps is often more persuasive than a broad pipeline overview with limited depth on each product.

IntelGenx Corp. (IGX) pitch deck: common questions

What does IntelGenx Corp. (IGX) do?

IntelGenx is a Canadian specialty pharmaceutical company that develops and manufactures **oral thin film drug delivery** products using its proprietary VersaFilm™ technology, repurposing existing drugs and creating generics with improved convenience, bioavailability, and lifecycle management.

What fundraising or financing activity was associated with this IntelGenx investor deck?

The deck served as an **investor presentation for public‑market investors** in late 2015/early 2016, around the time IntelGenx reported record Q3 2015 results and highlighted its pipeline and partnerships; it does not appear to be tied to a single private equity or venture round but rather to ongoing capital markets and strategic partnership efforts.

Which key products and indications are highlighted in the IntelGenx pitch deck?

The deck emphasizes **RIZAPORT® (rizatriptan oral thin film) for migraines**, a **Tadalafil VersaFilm™** product for erectile dysfunction, and an **oral thin film loxapine formulation** for schizophrenia and bipolar I disorder, alongside four generic products partnered with Chemo Group.

Who are IntelGenx’s main commercialization and development partners in this deck?

IntelGenx’s oral thin film strategy is built on partnering: **RedHill Biopharma** for RIZAPORT® migraines, **Chemo Group** for four generic products, **Grupo Juste** for Spain and certain territories, and **Pharmatronic** for South Korea, with IntelGenx typically receiving upfront payments, milestones, R&D revenues, and profit‑sharing.

What traction or milestones does IntelGenx report around the time of this deck?

According to the deck and contemporaneous materials, IntelGenx achieved record Q3 2015 results and 2015 profitability, obtained European marketing approval for RIZAPORT® in Germany (October 2015), and was constructing a dedicated oral film manufacturing facility, positioning itself for further regulatory submissions and launches.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• IGX Investor Presentation | PDF - Slideshare
• Igx Investor Presentation
• RedHill Biopharma and IntelGenx Submit New Drug Application to...
• IGXT Jan 6, 2017 Investor Presentation
• Intelgenx april 7-2016
• News
• 0001062993-16-008565
• RedHill Biopharma and IntelGenx Announce RIZAPORT...

IntelGenx Corp. (IGX) pitch deck slides

What each slide of the IntelGenx Corp. (IGX) pitch deck says

Slide 1

\ TSX-V: IGX OTCOX: IGXT Innovative Drug Delivery Solutions Investor Presentation March 10, 2017 WE MAKE APPROVED DRUGS BETTER

Slide 2

Forward Looking Statements To the extent any statements made in this presentation contain information that is not historical, these statements are forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forwardlooking statements. expect," "intend," "plan,' Forward-looking statements are identified by words such as "believe," "anticipate, 'will," "may" and other similar expressions…

Slide 3

Company Snapshot BN - { ¢ IntelGenx Corp. Founded 2003 o TSX-V (IGX) CAD$1.03 x * OTCQX (IGXT) US$0.76 he e Market Capitalization US$50M « e Shares Issued 65.4M —& «Shares Fully Diluted 70.8M * Insider Ownership 15% e Cash/Equivalent (as of sept 30, 2016) USS$5.7M Analyst Coverage ~ Firm Analyst Au Nr H.C. Wainwright Swayampakula Ramakanth Q : Singular Research Greg Eisen weds KE Ripa 210. IntelGen, corp. i =

Slide 4

Advantages of Oral Thin Film Delivery We are focused on areas where oral films are particularly well-suited: Develop and commercialize products that provide therapeutic advantages to patients leveraging oral films, such as: + Reduced side effects + Improved bio-availability a ' + Response time versus existing drugs + Lifecycle management :'\ + Repurpose existing drugs for new indications using oral films m J + "First-to-file" Generic drugs where high technology barriers to entry exist in reproducing branded films IntelGen, corp.

Slide 5

Clearly Defined BD Strategy NN Balancing Risks and Opportunities for an Optimized Portfolio IntelGenx Future Focus Deal Value Low (itec le Mgmt ® Low O Medium (Patient Benéits oO High Repurpos Overall = . Risk OFTF Generics High Slow Time to Market Fast IntelGen, Corp.

Slide 8

Strategic Partnership with Chemo Group Licensing and development agreements entered for four generic products * IntelGenx granted Chemo exclusive worldwide license to commercialize two generic tablets and U.S. license for two other generic oral films * IntelGenx to receive upfront, milestone, R&D revenues and AbeutChemo Group: s, s + 5,000 employees share of profits — total value of 7 digits - Haad ofmba LSpal + Revenues of $1.2B annually « Markets over 300 products * Combined total market of four products is over $7B i i . W + 20 state-of-the-art facilities * 9 specialized R&D centers * Chemo making a strategic move into novel drug delivery products with IntelGenx as its partner * Partners…

Slide 9

VersaFilm For Migraines Leverages VersaFilm™ Technology w + European Mktg Approval — November 2015 + Co-development partnership with RedHill Biopharma + Definitive agreement signed July 2016 with Grupo Juste for Spain & additional territories + Definitive agreement signed Dec 2016 with Pharmatronic for South Korea « Actively pursuing several opportunities to open new markets - negotiations with future commercialization partners ongoing + Planned USA submission to FDA Q3/17 + Expected USA approval Q1/18 o IntelGen, IntelGen, corp.

Slide 10

For Erectile Dysfunction VersaFilm - Granted license from Lilly for Tadalfil ED dosing patent '166 Will allow entry of Tadalafil VersaFilm™ into the ED US market upon FDA approval, potentially before the market entry of Cialis® generic competitors Accelerates our partnering of this product m. &W VersaFilm Containing tadalafil (Cialis® - Eli Lilly), Ty / a leading molecule in the ED market Demonstrated bioequivalence to Cialis® Orally disintegrating films without need for water provide unprecedented patient convenience and a discrete dosing alternative 505(b)(2) USA NDA submission in Q2/17 Expected USA approval H1/2018 IntelGen, corp. 10

Slide 11

f ine, For Schizophrenia & Bipolar VersaFllm Disorder * The first oral thin film using IntelGenx proprietary drug delivery technology, VersaFilm™, for treatment of schizophrenia & bipolar 1 disorder » Fast-acting loxapine oral dosage — to treat acute agitation and anxiety in noninstitutionalized patients with schizophrenia & bipolar 1 disorder * Reduces risk of pulmonary problems and potential risk of violence and injury to patients and others * Formulation optimization stage — results expected H2 2017 IntelGen, corp.

Slide text above is read directly from the IntelGenx Corp. (IGX) deck PDF embedded on this page.

Related fundraising guides (24)

• Curio.io Pitch Deck Teardown: Selling High-Engagement Audio Journalism
• Layla Pitch Deck Teardown: A $3M Seed Round Built on AI-Powered Travel Discovery
• Hone Pitch Deck Teardown: Defining the 'Missing Middle' of Corporate Learning
• Halp Pitch Deck Teardown: A 7-Slide Memo Strategy for a $4M Seed Round
• Factorial Pitch Deck Teardown: A Narrative-Driven Series C Strategy for HR Tech
• Domino Data Lab Pitch Deck Teardown: A Masterclass in Enterprise Social Proof
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Bringg Pitch Deck Teardown: A Masterclass in Enterprise SaaS Traction and Scale
• authID.ai Pitch Deck Teardown: A Post-IPO Roadmap for Biometric Identity Verification
• airSlate Pitch Deck Teardown: A $51.5M Series C Masterclass in Growth and Product Consolidation
• Nest Health Pitch Deck Teardown: A $15M Seed Strategy for Value-Based Family Care
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• Martian Pitch Deck Teardown: A $9M Seed Masterclass in LLM Orchestration and Interpretability
• HMNC Brain Health Pitch Deck Teardown: A Precision Psychiatry Play for Depression
• Groundcover Pitch Deck Teardown: Leveraging eBPF to Disrupt Cloud Observability Costs
• EVERY Pitch Deck Teardown: A $175M Masterclass in Precision Fermentation Storytelling
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Claira Pitch Deck Teardown: Solving the Legal Logic Gap in Financial Contracts
• Bravo Sierra Pitch Deck Teardown: Leveraging Military Community for CPG Scale
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• Friday Finance Pitch Deck Teardown: A $20M Series A Built on Aggregation and Social Proof
• Orchid Pitch Deck Teardown: A Masterclass in High-Stakes Clinical Validation
• RegioHelden Pitch Deck Teardown: A Masterclass in Local Marketing Unit Economics
• Leonardo.ai Pitch Deck Teardown: A Product-First Showcase of Generative AI Traction

Decks from the same year (1)

• 2015 pitch deck examples

Decks from the same region (1)

• Canadian pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with I

More pitch deck teardowns (16)

• Instructure Pitch Deck Teardown: Scaling the Modern Learning Management System
• Instructure Pitch Deck Teardown: Scaling EdTech Through Multi-Year Contract Visibility
• Instructure Pitch Deck Teardown: Scaling EdTech into Enterprise Talent Management
• Instructure Pitch Deck Teardown: Scaling EdTech Through Efficiency and Global Expansion
• Instructure Pitch Deck Teardown: A Masterclass in Post-IPO Investor Relations Transparency
• Intech Harness Pitch Deck Teardown: Solving Irrigation Inefficiency with Patented IoT Hardware
• Intelen Pitch Deck Teardown: Gamifying Energy Efficiency for Smart Grids
• IntelGenX Pitch Deck Teardown: A Case Study in Pharmaceutical Manufacturing and Licensing
• Intercom Pitch Deck Teardown: A Masterclass in Early-Stage Product Focus
• Intercom Pitch Deck Breakdown: How to Sell a Category-Defining Vision
• Intercom Pitch Deck Teardown: A Lean, Problem-Focused Seed Round Pitch
• Intergalactic Enterprises Pitch Deck Teardown: A Massive Vision for Global Golf Entertainment
• InternSource Pitch Deck Teardown: A Badging-Led Approach to the Internship Market
• Interpace Diagnostics Pitch Deck Teardown: Validating Molecular Cancer Risk Classifiers
• Intersailclub Pitch Deck Teardown: A Niche Travel Marketplace Betting on Cabin-Level Booking
• IntroPls Pitch Deck Teardown: A Crowd-Sourced Recruitment Model for the Singapore Market

Recently published pitch deck teardowns (12)

• Deskdoo Pitch Deck Teardown: A Cloud Operating System for the Pre-Pandemic Remote Era
• Finqware Pitch Deck Teardown: Leveraging Open Banking for Mid-Market Treasury Management
• Desert Haven Pitch Deck Teardown: A Grant-Heavy Model for Nevada Affordable Housing
• diabetesProject Pitch Deck Teardown: A Data-Driven Hub for Insurance Incentives
• Diablo Pitch Deck Teardown: The 1994 Vision for a 'Neglected Niche' in Gaming
• Thinaire Pitch Deck Teardown: A Dense Technical Vision for Proximity Marketing
• Digital Donations Technologies Pitch Deck Teardown: A Multi-Channel Philanthropy Ecosystem
• donkidrive Pitch Deck Teardown: A Peer-to-Peer Logistics Play for the South African Market
• Dotty AR Pitch Deck Teardown: A Heavy Industry Approach to Enterprise Telepresence
• Drive Pitch Deck Teardown: A Community-Led Hyperlocal Car Rental Marketplace
• Drive Pitch Deck Teardown: A Hyper-Local P2P Car Rental Play in the Philippines
• Dynamaxx Clinics SPV I LLC Pitch Deck Teardown: A $1M Regional Medical Spa Rollout

Fundraising library · Pitch deck examples · Investor directory · Founder database